Clinical trial

SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary…

NCT00180310 · Abbott Medical Devices, Industry · Completed

Key facts

NCT number NCT00180310
Title SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System
Official title A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions
Acronym SPIRIT II
Lead sponsor Abbott Medical Devices, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Intervention type Device
Interventions XIENCE V® Everolimus Eluting Coronary Stent, TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
Enrollment 300
Start date Jul 1, 2005
Primary completion Jul 1, 2007
Completion Feb 1, 2011
First posted Sep 16, 2005
Last update posted Jul 20, 2011
Countries Austria, Belgium, Denmark, France, Germany, India, Italy, Netherlands, New Zealand, Poland, South Africa, Spain and 1 more

At a glance

  • 10–99 Study sites
  • No Results posted
  • 1–9 Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies